Ozempic, Wegovy, other GLP-1RA drugs not linked to increased pancreatic cancer risk, study finds
Posted:
New research has concluded that drugs from the glucagon-like peptide-1 receptor agonists (GLP-1RA) class do not increase the risk of pancreatic cancer.
Wearable medical devices are changing healthcare delivery by shifting care beyond traditional settings and bringing it closer to patients’ daily lives. By offering continuous monitoring, promoting patient engagement and supporting remote interventions, these technologies are becoming an essential part of…
Attendees
Sponsors and Exhibitors
Agenda 2025
Contact us